Related Experiment Video

Updated: May 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Metabolic syndrome and atrial fibrillation in patients with essential hypertension

G Vyssoulis1, E Karpanou, D Adamopoulos

  • 1Hypertension Unit, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, Athens, Greece.

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|July 26, 2011
PubMed

Insights

Metabolic syndrome (MS) is directly linked to a higher prevalence of atrial fibrillation (AF) in hypertensive patients. This association remained significant regardless of the MS definition used, highlighting a key risk factor.

Area of Science:

  • Cardiology
  • Metabolic Diseases
  • Epidemiology

Background:

  • Metabolic syndrome (MS) is increasingly linked to atrial fibrillation (AF) risk in the general population.
  • The relationship between MS and AF in hypertensive individuals requires further investigation.

Purpose of the Study:

  • To investigate the independent association between metabolic syndrome (MS) and atrial fibrillation (AF) in a large cohort of hypertensive patients.

Main Methods:

  • A cohort of 15,075 non-diabetic patients with essential hypertension underwent clinical, lipidemic, and ECG assessments.
  • Metabolic syndrome (MS) was diagnosed using five definitions, including ATPIII and GISSI Score.
  • Logistic regression analysis was employed to determine the independent association between MS and AF.

Main Results:

  • The prevalence of MS ranged from 31.7% to 47.8% based on the definition used.
  • MS was independently associated with AF presence (OR 1.61–1.99, p < 0.001) across all definitions.
  • All components of the ATPIII MS definition were independently linked to increased AF incidence, with AF prevalence rising with the number of MS components.

Conclusions:

  • Metabolic syndrome (MS) is directly and independently associated with atrial fibrillation (AF) prevalence in non-diabetic hypertensive patients.
Abstract

More Related Videos

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...